Acadia Pharma (ACAD) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $27.29 -0.58%
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +19.3%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.45), $0.07 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $17 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Increasing unusual option volume: ACAD ALHC PLAY FPS ITUB NAVN WVE UAL XEL
- Anthropic delays planned IPO from October to November - WSJ
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
